Island Pharmaceuticals has begun scheduled surgical preparations for 22 non-human primates at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) ahead of its Galidesivir dose-optimization study targeting Marburg virus disease. The study will evaluate different Galidesivir doses and treatment starting times in 20 animals, with two additional animals reserved as backups, to identify an effective treatment approach. Drug dosing is expected to begin in early December 2026, and the results will help guide the company's planned pivotal efficacy study under the FDA Animal Rule pathway.
